[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100429620":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":39,"responsibleParty":58,"collaborators":12,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":12,"enrollmentInfo":70,"targetDuration":12,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":42,"whyStopped":12,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"blood culture-based diagnostic strategy","NO_INTERVENTION","Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a blood culture-based diagnostic strategy",null,{"label":14,"type":15,"description":16,"interventionNames":17},"C. glabrata \u002F krusei PCR diagnostic strategy","EXPERIMENTAL","Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a diagnostic strategy based on C. glabrata \u002F krusei PCR",[18],"Diagnostic Test: Diagnosis strategy based on C. glabrata \u002F krusei PCR",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DIAGNOSTIC_TEST","Diagnosis strategy based on C. glabrata \u002F krusei PCR","For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata \u002F krusei PCR is negative",[14],[26],{"name":27,"affiliation":5,"role":28},"Pamela CHAUVIN, MD","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":12,"email":34},"Pamela CHAUVIN","CONTACT","05 67 69 04 09","chauvin.p@chu-toulouse.fr",{"name":36,"role":32,"phone":37,"phoneExt":12,"email":38},"Xavier IRIART","05 67 69 04 99","iriart.x@chu-toulouse.fr",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Uh Toulouse","RECRUITING","Toulouse","Occitanie","31000","France","FR",{"type":49,"coordinates":50},"Point",[51,52],1.44367,43.60426,{"lat":52,"lon":51},[55],{"name":56,"role":32,"phone":12,"phoneExt":12,"email":57},"PAMELA CHAUVIN, MD","CHAUVIN.P@CHU-TOULOUSE.FR",{"type":59,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100429620","candida-pcr-diagnosis-strategy-in-patients-from-intensive-care-units-100429620",false,"NCT04874441","Candida PCR Diagnosis Strategy in Patients From Intensive Care Units","Evaluation of the Effect of the Implementation of a Candida PCR Diagnosis Strategy on the Time Required to Obtain Results in Patients From Intensive Care Units With Suspected Systemic Invasive Candidiasis: Pilot Study","CANDI-PCR","Inclusion Criteria:\n\n* Patient affiliated or benefiting from a social protection system\n* Patient (or his\u002Fher trusted person) having given free and informed written consent to the investigating physician\n* Non-neutropenic patient hospitalised in the Toulouse University Hospital intensive care unit.\n* Patient with suspected invasive candidiasis for whom a blood culture for fungal infection diagnosis was taken and for whom an empirical treatment with echinocandin at an adapted dose was implemented.\n\nExclusion Criteria:\n\n* Patients under guardianship or trusteeship, persons under court protection\n* Pregnant or breastfeeding patients.","ALL","18 Years",{"count":71,"type":72},120,"ESTIMATED","INTERVENTIONAL",[75],"NA","The aim of this study is to evaluate the implementation of a new technique for invasive candidiasis diagnosis by PCR. The main objective will be to evaluate the effect of this strategy on the time required to obtain results in patients from intensive care units with suspected systemic invasive candidiasis. This PCR method could allow an antifungal switch to be made earlier, limiting the appearance of resistance and reducing the cost of antifungals for healthcare facilities.",[78],"Candida",[80,81,82,83],"candidemia","Polymerase Chain Reaction","DNA","antifungal agents","2024-08-01",{"date":86,"type":87},"2024-08-02","ACTUAL",{"date":89,"type":87},"2022-05-19",{"date":91,"type":72},"2025-08-01",{"name":5,"class":6},1]